Financial Performance - As of March 31, 2024, Vivani Medical reported a cash balance of 31.0million,anincreaseof9.0 million from 22.0milliononDecember31,2023[8]−ResearchanddevelopmentexpensesforQ12024were3.7 million, a decrease of 6% from 4.0millioninQ12023[9]−GeneralandadministrativeexpensesforQ12024were2.5 million, down 5% from 2.6millioninQ12023[10]−ThenetlossforQ12024was6.0 million, a slight decrease from 6.3millioninQ12023[13]−Totalassetsincreasedto53.8 million as of March 31, 2024, compared to 45.8milliononDecember31,2023[21]−Thetotalstockholders′equityroseto28.7 million as of March 31, 2024, up from 20.8millionattheendof2023[21]DevelopmentPipeline−VivaniplanstosubmittheINDapplicationforNPM−115inthesecondhalfof2024andinitiateafirst−in−humantrialthereafter[12]−InFebruary2024,VivaniannouncedpositivepreclinicaldataforNPM−115,showingapproximately2015 million registered direct offering in March 2024 to accelerate development programs and fund operations into the second half of 2025[5]
Vivani Medical(VANI)2024-05-13 20:57